Compare Amphastar Pharmaceuticals Inc (AMPH) vs Coupang Inc (CPNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Coupang Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.87 (market cap $868.62M), while Coupang Inc trades at $16.56 (market cap $29.66B). The key difference: Coupang Inc is far larger — about 34.1× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CPNG | |
|---|---|---|
Market Cap | $868.62M | $29.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $33.53 |
52-Week Low | $16.87 | $15.12 |
Enterprise Value | $1.27B | $29.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
CPNG trades at $16.55, up 2.22% today, with a neutral technical signal and bearish moving averages. Revenue grew to $34.53B in 2025, but recent quarters missed EPS expectations, and 2026 projects a net loss. The stock is undervalued relative to analyst consensus targets near $23.38, supported by strong cash flow from operations of $1.77B in 2025.
Outlook remains mixed due to near-term profitability challenges, but long-term growth in South Korean e-commerce and expansion into Taiwan offer upside. Risks include competitive pressures, regulatory fines, and execution on margin improvement. Analyst sentiment is overwhelmingly bullish with 87.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →
